Envision Pharma Group
PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
"I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space," shares Meg Heim, CEO of Envision Pharma Group. "His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness."
Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai's portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.
Anvar shares, "It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients' outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I'm so excited to be working with the Envision team to transform the industry as we know it."
Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, "It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights."
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.
Contact Information:
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856
SOURCE: Envision Pharma Group
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/761331/OKRAai-an-Envision-Pharma-Group-Company-Appoints-Dr-Yahya-Anvar-to-Senior-Leadership-Position
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release
Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust
FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release
WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr
QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release
BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease15.7.2025 09:50:00 CEST | Press release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce Partnership Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-
IXOPAY Surges Past 500 Certified Adapters, Solidifies Leadership in Enterprise-Grade Payment Orchestration15.7.2025 06:00:00 CEST | Press release
With 200 PSPs and 300 payment methods, IXOPAY is unlocking faster global expansion, improved approval rates, and full-stack control for enterprise merchants. LEHI, UT / ACCESS Newswire / July 15, 2025 / As global commerce accelerates, enterprise merchants are hitting a wall - their legacy payment stacks weren't built for the scale, complexity, or speed modern commerce demands. To stay competitive, merchants need infrastructure that adapts across markets, providers, and payment methods without costly rewrites or vendor lock-in. IXOPAY, a global leader in enterprise-grade payment orchestration, is addressing that challenge head-on with the announcement it has reached 500 certified adapters, connecting 200 payment service providers (PSPs) and 300 payment methods through a single, vendor-agnostic API. Payment orchestration is rapidly emerging as vital infrastructure for modern payments, and its effectiveness depends on the scale and breadth of the adapter ecosystem. IXOPAY's industry-leadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom